Cardiac, Metabolic Morbidity Highly Prevalent in Patients with Alopecia Areata
The largest study examining the relationship between alopecia areata and cardiovascular disease in a US cohort is reviewed.
The largest study examining the relationship between alopecia areata and cardiovascular disease in a US cohort is reviewed.
The prevalence of comorbidities in pediatric patients with alopecia areata was determined, using a large de-identified aggregated patient database.
For patients with chronic alopecia areata, fractional laser treatment may present a therapeutic alternative.
Antihistamine treatment in conjunction with SC and TC treatment shows hair regrowth in patients with alopecia areataꟷwith no known adverse events.
The FDA has granted Breakthrough Therapy designation to CTP-543 (Concert Pharmaceuticals), an oral Janus kinase (JAK) inhibitor for alopecia areata.
Some antihistamines may serve as potential monotherapy or adjunct therapy for alopecia areata.
Insufficiency of T-regulatory cells, which maintain immune system equilibrium and inhibit proinflammatory cell responses, may be a factor in the pathogenesis of MDD.
The lower rate of severe COVID-19 infection in women and children may be because of their lower androgen receptor expression.
Shared familial mechanisms may underlie alopecia areata and major depressive disorder, and suggest a bidirectional association.
A novel patient-reported outcome measure allows scalp hair loss to be characterized into clinically meaningful gradations from 0% to 100% missing scalp hair.